摘要
目的：探讨细胞色素 P4502D6（CYP2D6）基因多态性对接受他莫昔芬（TAM）治疗 ER 阳性乳腺癌患者预后的影响。方法采用 PCR 法检测2010年3月～2011年3月106例接受 TAM治疗的 ER 阳性乳腺癌患者外周血 CYP2D6基因型，分别采用χ2检验和 Logistic 回归模型分析 CYP2D6基因多态性与患者临床参数和预后的关系。结果106例 ER 阳性乳腺癌患者中，CYP2D6基因 Wt／Wt 型48例，占45．3％；Wt／＊10型42例，占39．6％；＊10／＊10型16例，占15．1％。CYP2D6基因型与患者的年龄（χ2＝0．391，P ＝0．822）、肿瘤直径（χ2＝2．544，P ＝0．280）、组织类型（χ2＝3．600，P ＝0．165）、TNM分期（χ2＝2．785，P ＝0．246）以及腋窝淋巴结转移（χ2＝2．997，P ＝0．223）无相关性差异。Logistic 回归模型分析，CYP2D6基因＊10／＊10型较 Wt／Wt 型和 Wt／＊10型对接受 TAM治疗 ER 阳性乳腺癌患者3年、5年的无病生存有较高的风险。结论 CYP2D6基因＊10／＊10型 ER 阳性乳腺癌患者接受 TAM治疗预后较差，临床可在 TAM治疗前行 CYP2D6基因多态性检测以便合理用药。
Objective To discuss the effects of cytochrome P4502D6 （CYP2D6）gene polymorphism on prognosis of estrogen receptor （ER）-positive breast cancer patients treated with tamoxifen （TAM）therapy.Methods From May 2010 to May 2012,CYP2D6 genotype was detected in 106 cases of ER-positive breast cancer patients treated with TAMtherapy by PCR.The relationship between CYP2D6 polymorphism and clinical parameters and prognosis were analyzed by χ2 test and Logistic regression model.Results In 106 cases of ER-positive breast cancer patients treated with TAM therapy,48 cases of Wt/Wt type accounted for 45.3%,42 cases of Wt/＊10 type accounted for 39.6%,and 16 cases of ＊10 /＊10 type accounted for 15.1%.χ2 test showed CYP2D6 genotype was not significantly correlated with age （χ2 =0.391,P =0.822）,tumor size （χ2 =2.544,P =0.280）,histology （χ2 =3.600,P =0.165）,TNMstage （χ2 =2.785,P =0.246） and axillary lymph node metastasis （χ2 =2.997,P =0.223）.Logistic regression model showed compared with patients with Wt/Wt type and Wt/＊10 type,patients with ＊10 /＊10 type had higher risk for 3-year,5-year disease free survival of ER-positive breast cancer patients treated with TAMtherapy.Conclusion The prognosis of ＊10 /＊10 type ER-posi-tive breast cancer patients treated with TAMtherapy is poor,and we can detect CYP2D6 polymorphism before TAMtherapy to use drug rationally.
出处
《山东医药》
CAS
北大核心
2016年第42期17-20,共4页
Shandong Medical Journal
基金
河南省科技计划项目(142300410388)
